Decreased whole-body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients (Articolo in rivista)

Type

• Articolo in rivista (Classe)
• Prodotto della ricerca (Classe)

Label

• Decreased whole-body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients (Articolo in rivista) (literal)

Anno

• 2009-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

• 10.1152/ajpendo.90960.2008 (literal)

Alternative label

• Gastaldelli A, Casolaro A, Ciociaro D, Frascerra S, Nannipieri M, Buzzigoli E, Ferrannini E (2009)
  Decreased whole-body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients
  in American journal of physiology: endocrinology and metabolism
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Gastaldelli A, Casolaro A, Ciociaro D, Frascerra S, Nannipieri M, Buzzigoli E, Ferrannini E (literal)

Pagina inizio

• E225 (literal)

Pagina fine

• E230 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url

• http://www.ncbi.nlm.nih.gov/pubmed/19417125 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 297 (literal)

Rivista

• American journal of physiology: endocrinology and metabolism (Rivista)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• IFC - Istituto di fisiologia clinica, Università di Pisa (literal)

Titolo

• Decreased whole-body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients (literal)

Abstract

• Pioglitazone has been shown to reduce fasting triglyceride levels. The mechanisms of this effect have not been fully elucidated, but decreased lipolysis may contribute to blunt the hypertriglyceridemic response to a meal. To test this hypothesis, we studied 27 type 2 diabetes mellitus (T2DM) patients and 7 sex-, age-, and body mass index-matched nondiabetic controls. Patients were randomized to pioglitazone (45 mg/day) or placebo for 16 wk. Whole body lipolysis was measured [as the [(2)H(5)]glycerol rate of appearance (R(a))] in the fasting state and for 6 h following a mixed meal. Compared with controls, T2DM had higher postprandial profiles of plasma triglycerides, free fatty acid (FFA), and beta-hydroxybutyrate, and a decreased suppression of glycerol R(a) (P < 0.04) despite higher insulin levels [268 (156) vs. 190 (123) pmol/l, median (interquartile range)]. Following pioglitazone, triglycerides and FFA were reduced (P = 0.05 and P < 0.04, respectively), and glycerol R(a) was more suppressed [-40 (137) vs. +7 (202) mumol/min of placebo, P < 0.05] despite a greater fall in insulin [-85 (176) vs. -20 (58) pmol/l, P = 0.05]. We conclude that, in well-controlled T2DM patients, whole body lipolysis is insulin resistant, and pioglitazone improves the insulin sensitivity of lipolysis. (literal)

Prodotto di

• Istituto di fisiologia clinica (IFC) (Istituto)

Autore CNR

• DEMETRIO CIOCIARO (Unità di personale interno)
• eleuterio ferrannini (Unità di personale esterno)
• EMMA BUZZIGOLI (Unità di personale interno)
• AMALIA GASTALDELLI (Persona)

Incoming links:

Autore CNR di

• DEMETRIO CIOCIARO (Unità di personale interno)
• AMALIA GASTALDELLI (Persona)
• eleuterio ferrannini (Unità di personale esterno)
• EMMA BUZZIGOLI (Unità di personale interno)

Prodotto

• Istituto di fisiologia clinica (IFC) (Istituto)
• http://www.cnr.it/ontology/cnr/individuo/modulo/ID6853

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• American journal of physiology: endocrinology and metabolism (Rivista)